Individuals with sickle cell disease (SCD) have increased inflammation, a high incidence of airway hyper-reactivity (AH) and increased circulating leukotrienes (LT). We show that binding to the HRE in the FLAP promoter. Therefore, it is likely that the intrinsically elevated levels of PlGF in SCD subjects contribute to increased LT, which in turn, mediate both inflammation and AH. Herein, we identify a mechanism of increased LT in SCD, and show HIF-1α as a hypoxia-independent target of PlGF. These studies provide new avenues to ameliorate these complications.
Introduction
Inflammation is increasingly recognized as central to the pathophysiology of sickle cell disease (SCD), and is manifest as leukocytosis, elevated levels of inflammatory cytokines, and activation of neutrophils, monocytes, and endothelial cells. [1] [2] [3] [4] It is present at steady state and is strongly associated with acute painful events, acute chest and early mortality. 5, 6 Current evidence strongly suggests that inflammation contributes to the endothelial cell dysfunction,
potentiates vaso-occlusion and may also give rise to the airway hyperreactivity (AH) that often accompanies SCD. [7] [8] [9] [10] Also intriguing is the spectrum of lung disease seen in this patient population, which spans from an increased incidence of AH and obstructive lung disease in children, [11] [12] [13] to restrictive lung disease and pulmonary vascular remodeling, which is associated with pulmonary hypertension in adults. [14] [15] [16] [17] [18] Leukotrienes (LT) mediate both inflammation and AH. [19] [20] [21] [22] Five lipoxygenase (5-LO) and its activating partner, five lipoxygenase activating protein (FLAP) catalyze the production of LT from arachidonic acid (AA) by generating 5-hydroperoxyeicostatraenoic acid (5-HPETE) and leukotriene A 4 (LTA 4 ). LTA 4 is the pivotal intermediate from which other LT i.e. LTB 4 and cysteinyl LT (CysLT) -LTC 4 , LTD 4 , and LTE 4 are formed. 20 LTB 4 is one of the most potent chemoattractant for neutrophils, eosinophils and mediator of inflammation. CysLT, on the other hand, are potent bronchoconstrictors that play an important role in edema, inflammation and mucus secretion in asthma, and were previously termed "slow releasing substances". 23 LT play an important role in the pathogenesis of inflammatory disorders, specifically asthma, rheumatoid arthritis and inflammatory bowel disease. [19] [20] [21] Studies by Bigby and coworkers 24, 25 have shown that both TNF-α and LPS induce the expression of FLAP in THP-1 cells. These studies showed the importance of NF-kB and C/EBP transcription factors in the LPS mediated FLAP expression. 24 For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From LTB 4 levels are higher in SCD patients at steady state, which are further increased in vasoocclusive pain crises (VOC) and acute chest syndrome (ACS). 26 Very recently, increased LTE 4 has been observed in patients with SCD, which is associated with a higher incidence of pain. 27 However, relatively less is understood about how LT are increased in SCD at the molecular level.
Placenta Growth Factor (PlGF) is an angiogenic growth factor with similar effects on endothelium as VEGF, and is primarily expressed by placental trophoblasts. [28] [29] [30] More recently, we and others show that erythroid cells, but not other hematopoietic cells, produce PlGF and its expression is high in SCD and thalassemia. 31, 32 VEGFR1 is its cognate receptor, which is expressed on endothelial cells, alveolar epithelial cells, mast cells and monocytes. We have previously shown that plasma levels of PlGF are high in SCD patients compared to control, which correlated well with SCD severity. 31 Moreover, we showed that mononuclear cells (MNC) of SCD patients were in activated state as demonstrated by increased levels of cytochemokines (IL-1β, IL-8, MCP-1 and VEGF) as compared to healthy controls. 31 Treatment of MNC from healthy individuals with PlGF in vitro increased expression of the same cytochemokines as was seen in SCD, strongly suggesting that PlGF may contribute to increased cytochemokine expression from monocytes. The cytochemokines induced by PlGF are potent leukocyte activators and chemo-attractants 31, 33 Injection of a PlGF-adenovirus vector causes leukocytosis in mice. 34 These data suggest PlGF may contribute to leukocyte activation and leukocytosis in vivo. Conceivably, increased leukocytosis and leukocyte activation in SCD would lead to amplified levels of LT, resulting in AH. We hypothesized that the chronic inflammation 2,35 and increased incidence of AH in patients with SCD could be explained by the activation of monocytes by PlGF to induce LT production.
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In the present study, we show that MNC from SCD subjects at steady state show significantly increased expression of 5-LO and FLAP mRNA, both key catalytic components of the LT pathway, as compared with healthy controls. In addition, PlGF increased FLAP mRNA expression and LT production from peripheral blood monocytes (PBM) and THP-1 monocytic cells. We find that PlGF activated PI-3 kinase, NADPH-oxidase and hypoxia-inducible factor (HIF-1α) to increase FLAP expression. Our studies show, for the first time, to the best of our knowledge, a hypoxia-independent role of HIF-1α in the regulation of FLAP and define some of the mechanisms behind the non-erythroid phenotypic presentations of SCD, and open new avenues for targeted therapeutic approaches.
Materials and Methods

Cells and reagents
All blood samples were obtained from children with homozygous SCD at steady state at their elective clinic appointment with routine clinical blood draws, using IRB approved protocols at Cincinnati Children's Hospital and with informed consent in accordance with the Declaration of Helsinki. Peripheral blood monocytes were isolated from EDTA blood from healthy volunteers after obtaining informed consent according to a protocol approved by the IRB at USC-LAC Hospital. To ensure values represent true steady state, samples were obtained from patients who had no acute sickle events, fever, infections 3 weeks prior, or 3 weeks after the blood draw and were not transfused within the last 90 days. Complete blood counts on the SCD patients revealed a WBC count of 11,600±1,400/µL, hemoglobin of 9.5±0.4g/dL, and platelets 466,000±63,400/µL. The proportion of eosinophils in the WBC fraction, and the absolute eosinophil count (340±90; n=9) were normal; and reticulocytes were elevated, as expected (8.5±1.7%). Complete blood counts were not performed on normal controls. Four of nine patients were on hydroxyurea. MNC were isolated as described, 31 
Estimation of intracellular reactive oxygen species (ROS)
Briefly, THP-1 (2×10 6 cells) were washed with PBS, incubated with 5µM 2',7'-dichlorofluorescein-diacetate dye 39 in RPMI at 37°C for 30min in the dark, then washed thrice with PBS to remove excess dye, and stimulated with PlGF for 4hr. Fluorescence intensity was analyzed for 60sec using RF-551 spectrofluorometric detector (Shimadzu, Kyoto, Japan) with excitation at 488nm and emission at 525nm. THP-1 cells loaded with the dye for 30min were used as a blank control.
Western blot analysis
The cytosolic and nuclear extracts were prepared from THP-1 cells as described. 40 Briefly, 5x10 6 cells were washed and resuspended in 400μl of cell-lysis buffer for 20min. The homogenate was centrifuged at 10,000g for 30sec and cytosolic supernatant was collected.
The nuclear extract was obtained by resuspending nuclear pellet in 50μl of nuclear extraction buffer on ice for 60min. The cytosolic extracts were used to analyze FLAP and PHD-2 protein while nuclear extracts were subjected to HIF-1α and HIF-1β analysis. The protein bands were detected with Immunobilon western reagents (Millipore Corporation, Billerica, MA).
The mutagenesis of human FLAP promoter
Mutant constructs of the human FLAP-Luc promoter were generated using wild type -371 FLAPLuc construct as a template by the Quick Change site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) using the primers shown in Table 1 . The double mutant of HIF-1α binding sites, represented as HRE-M1+2 was generated using HRE-M1 as a template. Mutations were confirmed by sequencing. 
Electrophoretic mobility shift assay (EMSA) for transcription factor HIF-1α
The single stranded oligonucleotides (Table 1) were biotin labeled using a Lightshift Chemiluminescent EMSA kit (Pierce, Rockford, IL) 42 and the complementary strands were annealed in equimolar ratios for 1hr at 37°C. The DNA binding reaction included nuclear protein extract (5µg), 5% glycerol, 5mM MgCl 2 , 50ng/µl poly(dI·dC), 0.05% NP-40 and 0.5ng biotinylated probe and incubated at room temperature for 20min. The specificity of DNA-protein interaction was demonstrated using 50-fold excess of unlabeled probe. For supershift assays, nuclear extracts were pre-incubated for 1hr on ice with HIF-1α antibody (2µg). The samples were then subjected to non-denaturing 6% polyacrylamide gel electrophoresis in 0.5×TBE, transferred to a Hybond-N + nylon membrane (Amersham Biosciences, Piscataway, NJ) followed by detection with streptavidin-HRP/chemiluminescence. Table 1 . The PCR products were subjected to agarose gel electrophoresis followed by densitometric analysis. The values were normalized to input DNA.
Statistical Analysis
Control and PlGF treated cells were compared by Student's t-test. One-way ANOVA followed by Turkey-Kramer test was used for multiple comparisons using the Instat-2 software program (GraphPad, San Diego, CA). Values of p<0.05 were considered statistically significant.
Results
MNC of SCD subjects express increased levels of 5-LO and FLAP mRNA at steady state
We first examined whether expression of 5-LO and FLAP, key regulatory enzymes in LT formation, were affected in MNC from SCD subjects. As shown in Figure 1A , (Figure 2A ). However, these cells did not release LTB 4 , as has been previously observed. 45 Moreover, pretreatment of THP-1 cells with an antibody to VEGFR1 or pharmacological inhibitors for PI-3 kinase (LY294002), NADPH-oxidase (DPI), FLAP (MK866) and phospholipase C (PLC) (U73122) reduced PlGF mediated LTE 4 release by 95±4%, 78±9%, 88±4%, 94±4%, and 97±5% respectively ( Figure 2B ). Leukotriene agonists can release arachidonic acid upon receptor activation followed by cPLA 2 activation within seconds. However, we did not observe an effect on LTE4 production at early time points ( Figure S3 ). PlGF also caused a 4-fold (423±22%) increase in the release of LTE 4 from PBM ( Figure 2A ).
PlGF induced FLAP expression involves activation of PI-3 kinase, NADPH oxidase and HIF-1α
As shown in Figure 2C , PlGF induced FLAP mRNA expression was inhibited by VEGFR1
antibody (93±4%), LY294002 (75±3%), DPI (98±4%) and R59949 (84±7%), the latter being a putative inhibitor of HIF-1α. However, inhibitors of NF-κB (PDTC), p38MAP kinase (SB203580) and MAP kinase (PD98059) did not inhibit PlGF-induced FLAP expression. Since DPI inhibited
FLAP expression, we determined whether PlGF increased the formation of ROS in THP-1 cells.
As shown in Figure 2D , PlGF caused a 6-fold (598±54%) increase in ROS formation, which was attenuated by VEGFR1 antibody (71±9%) and DPI (57±2%), while LY294002 and SB203580 did not affect ROS formation. These results indicate that PlGF binding to VEGFR1 causes activation of NADPH-oxidase to generate ROS, which is independent of the PI-3 kinase pathway.
We wanted to determine whether a similar effect of PlGF can be seen on the FLAP protein levels. As shown in Figure 3A , PlGF caused a time dependent (6-24hr) increase in FLAP protein expression. There was a 2.6-fold (266±9%) increase in FLAP protein at 24hr, which was significantly reduced by LY294002 and DPI by ~80%. Taken together, PlGF mediated FLAP expression involves activation of PI-3 kinase and NADPH oxidase.
PlGF induced HIF-1α mRNA and protein expression
It is well established that hypoxia increases HIF-1α protein levels but not HIF-1α mRNA. 46 In contrast, we observed that PlGF treatment of THP-1 cells increased HIF-1α mRNA expression in a time dependent manner (6-24hr) ( Figure 1D ). There was a 3-fold (299±8%) and a 2.5-fold (250±5%) increase in HIF-1α mRNA levels in THP-1 and PBM, respectively, at 24hr. As shown in Figure 2C , both VEGFR1 antibody and LY294002 reduced PlGF induced HIF-1α mRNA expression by ~80%, while DPI, R59949, PDTC, SB203580 and PD98059 did not affect HIF-1α mRNA levels. Although the ROS inhibitor, DPI, attenuated FLAP mRNA expression ( Figure 2C , lane 5), it did not reduce HIF-1α mRNA; therefore, we determined whether ROS exerted its effect on HIF-1α protein levels. As shown in Figure 3B , PlGF led to a time dependent (6-24hr) increase in HIF-1α protein levels in nuclear extracts of THP-1 cells, which was attenuated by stabilization through selective inhibition of PHD-2 protein levels in HepG2 cells. 47 Therefore, we analyzed the effect of PlGF on PHD-2 protein levels. As shown in Figure 4D , PlGF treatment of 
PlGF augments hypoxia-response element (HRE) promoter activity
Since PlGF mediated FLAP expression was attenuated by HIF-1α siRNA, we investigated whether this occurred via HREs, which are present in promoter regions of several genes regulated by HIF-1α. As shown in Figure 5A , PlGF caused a 5-fold increase in HRE-Luc activity, which was inhibited by LY294002 (53±5%) and transfection with PTEN (79±4%). In addition, transfection with HIF-1α siRNA reduced HRE-Luc activity by 77±3%, while scHIF-1α siRNA had no effect ( Figure 5B ). Moreover, HIF-1α overexpression showed a 5.5-fold increase in HRE-Luc activity, in the absence of PlGF. In contrast, overexpression of HIF-1β did not change HRE-Luc activity. These data show that PlGF induced HIF-1α expression can activate HRE.
PlGF mediated FLAP promoter activity requires HRE but not NF-κB binding site
Bigby and coworkers have shown that LPS induced FLAP expression in THP-1 cells required the binding of both NF-κB and C/EBP to its promoter. 24 As shown in Figure 5C , PlGF increased FLAP promoter activity by 5-fold (designated as 100% compared to the promoter less pGL3 vector). Analysis of serial deletion constructs of FLAP promoter showed that -371/+12bp region of the FLAP promoter had similar activity as the full length FLAP promoter, but -134/+12bp
promoter construct (lacking the HRE sites) showed reduced activity in response to PlGF ( Figure   5C ). Thus, we utilized -371/+12bp construct for further studies. This region of the FLAP promoter ( Figure 5D ) contains two putative consensus HRE (RCGTG) at -170 to -167bp and -251 to -248bp, one NF-κB binding site located at -43 to -34bp and two C/EBP consensus sites located at -36 to -28bp and -25 to -12bp, relative to transcriptional start site. We generated HRE mutant constructs of FLAP promoter, designated as HRE-M1 and HRE-M2 as indicated in Figure 5D . Additionally, we utilized HRE-M1 as a template to generate a construct having mutations in both HRE sites designated as HRE-M1+2. As shown in Figure 5E , tranfections with
For personal use only. on April 12, 2017. by guest www.bloodjournal.org From HRE-M1 and HRE-M2 showed reduced promoter activation by 66±2% and 40±3%, respectively.
However, HRE-M1+2 showed significantly higher inhibition (81±3%) in response to PlGF stimulation. In contrast, two different mutations of NF-κB site (NFkB-M1 and NFkB-M2) did not reduce PlGF mediated FLAP promoter activity. The role of HIF-1α in regulating FLAP promoter activity was also confirmed in PBM by utilizing HRE-M1+2 mutant construct of FLAP promoter.
As shown in Figure 5F , PBM transfected with -371FLAP promoter showed a 3.5-fold induction while HRE-M1+2 mutant FLAP promoter resulted in significant attenuation of promoter activity.
It is pertinent to note that FLAP promoter construct (-134/+12bp), lacking HRE sites, showed only a 50% reduction in PlGF mediated luciferase activity compared to -371/+12bp construct ( Figure 5C ), indicating a possible involvement of C/EBP sites in regulating FLAP promoter activity.
Next, we examined the role of PI-3 kinase and HIF-1α in FLAP promoter activity. As shown in Figure 5G , PlGF induced -371FLAP promoter activity was reduced by LY294002 (44±3%) but not by PD98059. Moreover, HIF-1α siRNA inhibited promoter activity by more than 80%, while scHIF-1α siRNA had no effect. Additionally, overexpression of HIF-1α but not HIF-1β resulted in a 5-fold increase in FLAP promoter activity, independent of PlGF stimulation. Taken together, these results suggest that PlGF mediated FLAP promoter activation requires both HRE sites but not NF-κB site located within the first 371bp of the FLAP promoter.
PlGF induces HIF-1α binding in vitro (EMSA) and in vivo (ChIP) to FLAP promoter
To further substantiate whether HIF-1α binds to HRE in the FLAP promoter, we utilized both wild type and mutant oligonucleotide flanking HRE site corresponding to -170 to -167bp region as probes for EMSA ( Table 1) . As shown in Figure 6A , nuclear extracts of PlGF treated cells 
Discussion
In this report, we showed that SCD patients at steady state expressed increased levels of 5-LO and FLAP mRNA in MNC, compared to healthy controls. Our studies further showed that PlGF upregulated FLAP mRNA to generate LT from PBM and THP-1 cells. A salient feature of SCD is inflammation, manifest as leukocytosis that occurs in the absence of acute infection or inflammation. 5, 6 It has been a dilemma to understand how a genetic defect in sickle RBC would result in leukocytosis and leukocyte activation at baseline. 2, 7, 31 Moreover, this leukocytosis correlates well with severity of disease and early mortality in two large studies 5, 6 , although a recent study did not find relationship. 48 Also seen is increased AH in children 9, 11, 49 and infants 50 in SCD. Moreover, LTB 4 26,51 and LTE 4 27 levels are found to be increased in SCD at baseline, which further increased during episodes of VOC and ACS. 26 Herein, we determined whether PlGF played a role in activation of monocytes to generate increased levels of LT, which would contribute to inflammation and asthma in SCD.
Styles and colleagues have shown increased levels of secretory phospholipase A 2 (sPLA 2 ) in association with development of ACS in SCD. 52 sPLA 2 releases AA from membrane phospholipids and has been implicated in the ACS. 52, 53 Increased AA can be acted upon by 5-LO and FLAP, resulting in production of LTB 4 and CysLT. Since PlGF levels are highly elevated in ACS in SCD 31 ; sickle monocytes are activated to generate cytochemokines 31, 33 , PlGF may play a role in ACS by contributing to both inflammation and AH.
Next, we examined the cellular signaling pathway for PlGF-mediated increased FLAP expression and LT release. We observed that PlGF-mediated FLAP expression and LTE 4 release was attenuated by antibody to VEGFR1 and inhibition of PI-3 kinase, NADPH-oxidase and HIF-1α. PlGF mediated LTE 4 release was also inhibited by inhibitors of FLAP (MK866) and PLC (U73122). Since U73122 inhibited the LTE 4 release, we examined if PlGF resulted in LTE 4 release at early time points, and found no effect (data not shown). Thus, it is possible that U73122 inhibits LTE 4 release at 24hr by inhibiting 5-LO, as has been previously reported. 54 PlGF mediated increase in HIF-1α mRNA occurred via activation of PI-3 kinase pathway, but not the NADPH-oxidase pathway. In contrast, activation of the NADPH-oxidase pathway increased HIF-1α protein levels, indicating that HIF-1α protein is stabilized by ROS pathway, as has been previously noted. 55, 56 However, the mechanism(s) by which PlGF stabilizes HIF-1α
protein in a hypoxia-independent manner remain unknown. Recent studies have shown that TGF-β1 induces HIF-1α stabilization through selective inhibition of PHD-2 47 , while nitric oxide mediated HIF-1α degradation involves PHD-2 activation 57 , indicating the role of PHD-2 in HIF-1α stabilization. However, we did not observe any change in PHD-2 protein levels in response to PlGF, suggesting that PlGF mediated ROS generation could conceivably inhibit PHD-2 enzyme activity by modifying the levels of various intracellular cofactors such as ascorbate, Fe
+2
and succinate, and thus stabilize HIF-1α. 58, 59 Previous studies have shown that LPS induced FLAP expression in THP-1 cells required the binding of both NF-κB and C/EBP to its promoter 24 and deletion analysis of the full length FLAP promoter (-3368/+12bp; accession # 60470) 60 revealed that the first 134bp of the promoter (-134/+12bp) were sufficient for TNF-α and LPS induced FLAP promoter activity. Our studies of deletion constructs of the FLAP promoter showed that -371/+12bp region was equally effective as the full length FLAP promoter in mediating the response to PlGF. Moreover, this effect was mediated via two HRE sites, unlike previously characterized NF-κB site in FLAP promoter.
Since mutations of HRE sites in the proximal promoter of FLAP (-371/+12bp) showed residual Notably, PlGF may have pleiotropic effect through multiple pathways in SCD, besides increasing LT. We have shown that PlGF increases cytochemokine release from MNC 31, 33 , which likely contributes to inflammation. This is supported by the evidence that PlGF knockout mice display blunted inflammatory response. 61, 62 We recently showed that PlGF induces expression of endothelin-1 from endothelial cells and endothelin-B receptor in monocytes, 42 molecules that likely contribute to the pulmonary artery hypertension seen in SCD. Notably,
CysLT generated by platelet-leukocyte interactions can also stimulate endothelial cells to release von Willebrand factor, which may further potentiate vascular occlusion. 63 Besides their effect on airways and smooth muscle, LT also promote adhesion of neutrophils to endothelial cells and the neutrophil-derived LTA 4 may contribute to the pool of LT. 64 Thus, LT may contribute to vascular occlusion and reactive air way disease in SCD. Recently, sickle mice have been shown to have an exaggerated propensity to experimentally-induced asthma. 65 These results would be important to confirm in vivo. We are currently investigating the role of PlGF and the 5-LO pathway in inflammation, acute vascular occlusions, ACS and AH in a prospective clinical study; and confirming the direct effects of PlGF in mouse models that simulate the chronic PlGF over-expression in SCD.
In conclusion, our studies show that PlGF, intrinsically released from erythroid cells caused activation of leukocytes, particularly monocytes, to generate increased levels of LT. We showed that the binding of PlGF to VEGFR1 led to activation of PI-3 kinase, NADPH-oxidase and HIF-1α. These data provide a novel mechanism of PlGF-induced FLAP expression which involves activation of HIF-1α in a manner that is independent of hypoxia. Thus, PlGF may provide a link between increased formation of LT, inflammation, vaso-occlusion and AH seen in SCD subjects.
Antagonists of the LT pathway, such as LT receptor antagonists, or zileuton, which are currently licensed for asthma 66 , could be utilized to ameliorate inflammation and AH in SCD patients. It is pertinent to mention that zileuton is structurally similar to hydroxyurea, has been shown to increase hemoglobin F production in primary erythroid cells in vitro, 67 and may have clinical utility in the treatment of SCD. 
